Dan Vilenski is credited with being among the very first to bring American high-tech companies to Israel. He led KulSo the Israeli branch of Kulicke and Soffa. He inspired the establishment of the Israeli branches of KLA-Tencor and Applied Materials and is a prime mover of Israel’s Nanotechnology Initiative. In 2004 these 3 companies export from Israel over 3 billion Dollars.
Vilenski, the former chairman of Applied Materials Israel, has championed bilateral trade and development through organizations such as the US-Israel Binational Industrial Research and Development (BIRD) Foundation (www.birdf.com), a position to which he was appointed in 1993; and he is a board member of the Israel National Nanotech Initiative.
Ms. Livnat Ben-Zur
Director
Livnat Ben-Zur is a seasoned healthcare investor and executive with over 25 years of experience spanning venture capital, company building, and global leadership roles across the medical device and biopharmaceutical sectors. As Chief Business Officer and Chief Technology Officer at NGT HealthCare II, she leads investment evaluation and portfolio companies’ value creation, with a strong focus on translating breakthrough scientific innovations into scalable, investable companies.
Livnat brings a distinctive combination of deep operational expertise and investor perspective, having led companies from early-stage development through clinical validation, regulatory approval, and commercialization. She has a proven track record of building and scaling healthcare ventures.
Prior to her role in venture capital, Livnat served as CEO of Corolabs and as General Manager of Regentis Biomaterials (NYSE RGNT), where she led the company through clinical development, strategic partnerships, to marketing approvals. Earlier in her career, she held senior business development and marketing roles at companies including Galil Medical and Medinol, playing key roles in fundraising, strategic expansion, and global market penetration.
Based in Nazareth, Livnat is also committed to impact-driven investing, promoting inclusive entrepreneurship and fostering collaboration between diverse communities. She is passionate about partnering with visionary founders and co-investors to build the next generation of high-impact healthcare companies.
Ms. Livnat Ben-Zur
Director
Livnat Ben-Zur is a seasoned healthcare investor and executive with over 25 years of experience spanning venture capital, company building, and global leadership roles across the medical device and biopharmaceutical sectors.
As Chief Business Officer and Chief Technology Officer at NGT HealthCare II, she leads investment evaluation and portfolio companies’ value creation, with a strong focus on translating breakthrough scientific innovations into scalable, investable companies.
Livnat brings a distinctive combination of deep operational expertise and investor perspective, having led companies from early-stage development through clinical validation, regulatory approval, and commercialization. She has a proven track record of building and scaling healthcare ventures.
Prior to her role in venture capital, Livnat served as CEO of Corolabs and as General Manager of Regentis Biomaterials (NYSE RGNT), where she led the company through clinical development, strategic partnerships, to marketing approvals. Earlier in her career, she held senior business development and marketing roles at companies including Galil Medical and Medinol, playing key roles in fundraising, strategic expansion, and global market penetration.
Based in Nazareth, Livnat is also committed to impact-driven investing, promoting inclusive entrepreneurship and fostering collaboration between diverse communities. She is passionate about partnering with visionary founders and co-investors to build the next generation of high-impact healthcare companies.